Home
About
Overview
Sharing Data
ORCID
Help
History (3)
Hemorrhage in intracerebral arteriovenous malformations: angiographic determinants.
The role of pharmacogenetics in cancer therapeutics.
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. JAMA Oncol. 2020 11 01; 6(11):1694-1695.
View in:
PubMed
subject areas
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Body Weight
Carcinoma, Non-Small-Cell Lung
Delivery of Health Care
Drug Administration Schedule
Drug Dosage Calculations
Drug Packaging
Humans
Lung Neoplasms
Melanoma
Patient Safety
Risk Assessment
Skin Neoplasms
Time Factors
authors with profiles
Mark J. Ratain